Document:

Exhibit 10.17

 

		Notice of Award	
	SMALL BUSINESS INNOVATION RESEARCH PROG        Issue Date:      08/16/2012
	Department of Health and Human Services 

National Institutes of Health
	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

 

Grant Number: 5R44AA019876-03

 

Principal Investigator(s):

Bert J. W. M. Oehlen, PHD

 

Project Title: Treatment for alcoholic liver
disease

 

Dr. Oehlen, Bert , PhD

Senior Research Scientist

1050 Stewart Avenue

Garden City, NY 115304888

 

Award e-mailed to: igoldberg@angion.com

 

Budget Period: 09/01/2012 – 08/31/2013

Project Period: 09/15/2010 – 08/31/2013

 

Dear Business Official:

 

The National Institutes of Health hereby awards a
grant in the amount of $1,223,250 (see “Award Calculation” in Section I and “Terms and Conditions” in Section
III) to ANGION BIOMEDICA CORPORATION in support of the above referenced project. This award is pursuant to the authority of 42
USC 241 42 CFR PART 52 15 USC 638 and is subject to the requirements of this statute and regulation and of other referenced, incorporated
or attached terms and conditions.

 

Acceptance of this award including the “Terms
and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

 

Each publication, press release, or other document
about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research
reported in this publication was supported by the National Institute On Alcohol Abuse And Alcoholism of the National Institutes
of Health under Award Number R44AA019876. The content is solely the responsibility of the authors and does not necessarily represent
the official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this
research, please notify the NIH awarding IC in advance to allow for coordination.

 

Award recipients must promote objectivity in research
by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under
NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance with
42 CFR Part 50 Subpart F. Subsequent to the compliance date of the 2011 revised FCOI regulation (i.e., on or before August 24,
2012), Awardees must be in compliance with all aspects of the 2011 revised regulation; until then, Awardees must comply with the
1995 regulation. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does
not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the
NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

 

If you have any questions about this award, please
contact the individual(s) referenced in Section IV.

 

Sincerely yours,

 

Judy Fox

Grants Management Officer

NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

 

	1	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

    	 

    	 

    

 

Additional information follows

 

	 	2	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

  

    	 

    	 

    

 

	 	SECTION I – AWARD DATA – 5R44AA019876-03

 

	Award
    Calculation (U.S. Dollars)	 	 	 
	 	 	 	 
	Federal Direct Costs	 	$	[***]	 
	Federal F&A Costs	 	$	[***]	 
	Approved Budget	 	$	[***]	 
	Fee	 	$	[***]	 
	Federal Share	 	$	[***]	 
	TOTAL FEDERAL AWARD AMOUNT	 	$	1,223,250	 
	 	 	 	 	 
	AMOUNT OF THIS ACTION (FEDERAL SHARE)	 	$	1,223,250	 

 

	SUMMARY
    TOTALS FOR ALL YEARS	 
	YR	 	THIS
    AWARD	 	 	CUMULATIVE
    TOTALS	 
	3	 	$	1,223,250	 	 	$	1,223,250	 

 

	Fiscal Information:	 
	CFDA Number:	93.273
	EIN:	1113430072A1
	Document Number:	RAA019876B
	Fiscal Year:	2012

 

	IC	 	CAN	 	2012	 
	AA	 	8470488	 	$	1,223,250	 

 

NIH Administrative Data:

PCC: AM Y / OC: 414E / Processed:
SIMONSJ 08/14/2012

 

	 	SECTION II – PAYMENT/HOTLINE INFORMATION – 5R44AA019876-03

 

For payment and HHS Office of Inspector General
Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

 

	 	SECTION III – TERMS AND CONDITIONS – 5R44AA019876-03

 

This award is based on the application submitted
to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly
or by reference in the following:

 

		a.	The grant program legislation and program regulation cited in this Notice of Award.

		b.	Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations
acts.

		c.	45 CFR Part 74 or 45 CFR Part 92 as applicable.

		d.	The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.

		e.	This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

 

(See NIH Home Page at ‘http://grants.nih.gov/grants/policy/awardconditions.htm’
for certain references cited above.)

 

Carry over of an unobligated balance into the next
budget period requires Grants Management Officer prior approval.

 

This award is subject to the requirements of 2 CFR
Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration
in the Central Contractor Registration. Should a consortium/subaward be issued under this award, a DUNS requirement must be included.
See http://grants.nih.gov/grants/policy/awardconditions.htm for the full NIH award term implementing this requirement and other additional information.

 

	 	3	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

 

This award is not subject to the Transparency Act
subaward and executive compensation reporting requirement of 2 CFR Part 170.

 

In accordance with P.L. 110-161, compliance with
the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: 
http://publicaccess.nih.gov/.

 

This award represents the final year of the competitive
segment for this grant. Therefore, see the NIH Grants Policy Statement Section 8.6 Closeout for closeout requirements at: 
http://grants.nih.gov/grants/policy/#gps .

 

A final Federal Financial Report (FFR) (SF 425) must
be submitted through the eRA Commons (Commons) within 90 days of the expiration date; see the NIH Grants Policy Statement Section
8.6.1 Financial Reports, http://grants.nih.gov/grants/policy/#gps, for additional information on this submission requirement.
The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. There must
be no discrepancies between the final FFR expenditure data and the Payment Management System’s (PMS) cash transaction data.

 

A Final Invention Statement and Certification form
(HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted through the eRA
Commons (Commons) within 90 days of the expiration date.

 

Furthermore, unless an application for competitive
renewal is submitted, a final progress report must also be submitted within 90 days of the expiration date. Institute/Centers may
accept the progress report contained in competitive renewal (type 2) in lieu of a separate final progress report. Contact the awarding
IC for IC-specific policy regarding acceptance of a progress report contained in a competitive renewal application in lieu of a
separate final progress report.

 

NIH strongly encourages electronic submission of
the final progress report and the final invention statement through the Closeout feature in the Commons. If the final progress
report and final invention statement are not submitted through the Commons, a copy can be emailed or sent to the contacts listed
below. Copies of the HHS 568 form may be downloaded at:  http://grants.nih.gov/grants/forms.htm.

 

Submissions of the final progress report and HHS
568 may be e-mailed as PDF attachments to the NIH Central Closeout Center at: DeasCentralized@od.nih.gov.

 

Paper submissions of the final progress report and
the HHS 568 may be faxed to the NIH Central Closeout Center at 301-480-2304 or mailed to the NIH Central Closeout Center at the
following address:

 

NIH/OD/OER/DEAS

Central Closeout Center

6705 Rockledge Drive, Room 2207

Bethesda, MD 20892-7987 (for regular or U.S. Postal
Service Express mail)

Bethesda, MD 20817 (for other courier/express mail
delivery only)

 

The final progress report should include, at a minimum,
a summary of progress toward the achievement of the originally stated aims, a list of significant results (positive and/or negative),
a list of publications and the grant number. If human subjects were included in the research, the final progress report should
also address the following:

 

Report on the inclusion of gender and minority study
subjects (using the gender and minority Inclusion Enrollment Form as provided in the PHS 2590 and available at 
http://grants.nih.gov/grants/forms.htm).

 

Where appropriate, indicate whether children were
involved in the study or how the study was relevant for conditions affecting children (see NIH Grants Policy Statement Section
4.1.15.7 Inclusion of Children as Subjects in Clinical Research
at URL  http://grants.nih.gov/grants/policy/#gps).

 

	 	4	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

 

Describe any data, research materials (such as cell
lines, DNA probes, animal models), protocols, software, or other information resulting from the research that is available to be
shared with other investigators and how it may be accessed.

 

Any other specific requirements set forth in the
terms and conditions of the award must also be addressed in the final progress report.

 

Note, if this is the final year of a competitive
segment due to the transfer of the grant to another institution, then not all the requirements stated above are applicable. Specifically
a Final Progress Report is not required. However, a final FFR is required and should be submitted electronically as noted above.
In addition, if not already submitted, the Final Invention Statement is required and should be sent directly the assigned Grants
Management Specialist.

 

Treatment of Program Income:

Additional Costs

 

	 	SECTION IV – AA Special Terms and Conditions – 5R44AA019876-03

 

This award is issued in accordance with the NIH fiscal
policies described in NIH Guide Notice NOT-OD-12-036

 

None of the funds in this award shall be used to
pay the salary of an individual at a rate in excess of the applicable salary cap. Current salary cap levels can be found at the
following URL: http://grants1.nih.gov/grants/policy/salcap_summary.htm

 

Intellectual property rights: Normally, the awardee
organization retains the principal worldwide patent rights to any invention developed with United States Government support. Under
Title 37 Code of Federal Regulations Part 401, the Government receives a royalty-free license for its use, reserves the right to
require the patent holder to license others in certain circumstances, and requires that anyone exclusively licensed to sell the
invention in the United States must normally manufacture it substantially in the United States.

 

Rights and obligations related to inventions created
or reduced to practice as a result of this award are detailed in 35 U.S.C. 205 and 37 CFR Part 401. These inventions must be reported
to the Extramural Invention Reporting and Technology Resources Branch, OPERA, NIH, 6701 Rockledge Drive, MSC 7750, Bethesda, MD
20892-7750, (301) 435-1986. For additional information, access the NIH link on the Interagency Edison web site (www.iedison.gov)which
includes an electronic invention reporting system, reference information and the text to 37 CFR 401.14(h).

 

To the extent authorized by 35 U.S.C., Section 205,
the Government will not make public any information disclosing an NIH-supported invention for a 4-year period to allow the awardee
organization a reasonable time to file a patent application, nor will the Government release any information that is part of that
patent application

 

The fee provided as part of this Notice of Award
is in addition to direct and facilities and administrative costs. The fee is to be drawn down from the HHS Payment Management System
in increments proportionate to the draw down of costs.

 

Allowable costs conducted by for-profit organizations
will be determined by applying the cost principles of Contracts with Commercial Organizations set forth in 48 CFR, Subpart 31.

 

As stated in Section III above, this award represents
the final year of the competitive segment for this grant. In addition to the closeout guidance described in Section III, please
note that the final report should be a presentation of the accomplishments of the Phase II effort. There is no form page for a
final progress report. It may be typed on plain white paper (or you may use the PHS2590 Continuation Page found at: http://grants1.nih.gov/grants/funding/2590/continuation.pdf).

 

The recommended length for the narrative portion
is 10 pages. The format and items to be included in the Phase II final progress report can be found in PHS 2590 Instructions for
SBIR and STTR Final Report Requirements in Chapter 7 located at http://grants2.nih.gov/grants/funding/2590/phs2590.pdf.

 

	 	5	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

  

STAFF CONTACTS

 

The Grants Management Specialist is responsible for
the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions.
The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work
together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should
be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

 

Grants Management Specialist: William F Caputo

Email: bcaputo@mail.nih.gov Phone:
301-443-2434 Fax: 301-443-3891

 

Program Official: Peter Gao

Email: gaozh@mail.nih.gov Phone: 301-443-6106
Fax: 301-594-0673

 

SPREADSHEET SUMMARY

GRANT NUMBER: 5R44AA019876-03

 

INSTITUTION: ANGION BIOMEDICA CORPORATION

 

	Facilities
    and Administrative Costs	 	Year
    3	 
	F&A Cost Rate 1	 	 	90	%
	F&A Cost Base 1	 	$	[***]	 
	F&A Costs 1	 	$	[***]	 

 

	 	6	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.Exhibit 10.18

 

		Notice of Award	
	SMALL BUSINESS INNOVATION RESEARCH PROG        Issue Date:      04/04/2012
	Department of Health and Human Services
	National Institutes of Health
	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

 

Grant Number: 1R43HL114298-01

 

Principal Investigator(s):

PRAKASH NARAYAN, PHD

 

Project Title: An Innovative Cardioprotective

 

Dr. Goldberg, Itzhak D, MD

Angion Biomedica Corp.

1050 Stewart Ave

Garden City, NY 115314888

 

Award e-mailed to: igoldberg@angion.com

 

Budget Period: 04/05/2012 – 03/31/2013

Project Period: 04/05/2012 – 03/31/2013

 

Dear Business Official:

 

The National Institutes of Health hereby awards a
grant in the amount of $373,934 (see “Award Calculation” in Section I and “Terms and Conditions” in Section
III) to ANGION BIOMEDICA CORPORATION in support of the above referenced project. This award is pursuant to the authority of 42
USC 241 42 CFR PART 52 15 USC 638 and is subject to the requirements of this statute and regulation and of other referenced, incorporated
or attached terms and conditions.

 

Acceptance of this award including the “Terms
and Conditions” is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

 

Each publication, press release, or other document
about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as “Research
reported in this publication was supported by the National Heart, Lung, And Blood Institute of the National Institutes of Health
under Award Number R43HL114298. The content is solely the responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health.” Prior to issuing a press release concerning the outcome of this research,
please notify the NIH awarding IC in advance to allow for coordination.

 

Award recipients must promote objectivity in research
by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under
NIH awards will be free from bias resulting from an Investigator’s Financial Conflict of Interest (FCOI), in accordance
with 42 CFR Part 50 Subpart F. Subsequent to the compliance date of the 2011 revised FCOI regulation (i.e., on or before August
24, 2012), Awardees must be in compliance with all aspects of the 2011 revised regulation; until then, Awardees must comply with
the 1995 regulation. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation
does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult
the NIH website http://grants.nih.gov/grants/policy/coi/ for a link to the regulation and additional important information.

 

If you have any questions about this award, please
contact the individual(s) referenced in Section IV.

 

Sincerely yours,

 

Mary S Baylor

Grants Management Officer

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

 

	1	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

 

    	 

    	 

    

 

Additional information follows

 

	 	2	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

 

	  	SECTION I – AWARD DATA – 1R43HL114298-01

 

	Award
    Calculation (U.S. Dollars)	 	 	 
	Salaries and Wages	 	$	[***]	 
	Fringe Benefits	 	$	[***]	 
	Supplies	 	$	[***]	 
	Travel Costs	 	$	[***]	 
	 	 	 	 	 
	Federal Direct Costs	 	$	[***]	 
	Federal F&A Costs	 	$	[***]	 
	Approved Budget	 	$	[***]	 
	Fee	 	$	[***]	 
	Federal Share	 	$	[***]	 
	TOTAL
    FEDERAL AWARD AMOUNT	 	$	373,934	 
	 	 	 	 	 
	AMOUNT OF THIS ACTION
    (FEDERAL SHARE)	 	$	373,934	 

 

	SUMMARY
    TOTALS FOR ALL YEARS	 
	YR	 	THIS
    AWARD	 	 	CUMULATIVE
    TOTALS	 
	1	 	$	373,934	 	 	$	373,934	 

 

	Fiscal Information:	 
	CFDA Number:	93.837
	EIN:	1113430072A1
	Document Number:	RHL114298A
	Fiscal Year:	2012

 

	IC	 	CAN	 	2012	 
	HL	 	8470242	 	$	373,934	 

 

NIH Administrative Data:

PCC: HHHAIN / OC: 414A / Processed:
PAGEM 04/02/2012

 

	 	SECTION II – PAYMENT/HOTLINE INFORMATION – 1R43HL114298-01

 

For payment and HHS Office of Inspector General
Hotline information, see the NIH Home Page at http://grants.nih.gov/grants/policy/awardconditions.htm

 

	 	SECTION III – TERMS AND CONDITIONS – 1R43HL114298-01

 

This award is based on the application submitted
to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly
or by reference in the following:

 

		a.	The grant program legislation and program regulation cited in this Notice of Award.

		b.	Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations
acts.

		c.	45 CFR Part 74 or 45 CFR Part 92 as applicable.

		d.	The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.

		e.	This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

 

(See NIH Home Page at ‘http://grants.nih.gov/grants/policy/awardconditions.htm’
for certain references cited above.)

 

Carry over of an unobligated balance into the next
budget period requires Grants Management Officer prior approval.

 

	 	3	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

This award is subject to the requirements of 2
CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an
active registration in the Central Contractor Registration. Should a consortium/subaward be issued under this award, a DUNS
requirement must be included. See  http://grants.nih.gov/grants/policy/awardconditions.htm for
the full NIH award term implementing this requirement and other additional information.

 

Based on the project period start date of this project,
this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170.
There are conditions that may exclude this award; see  http://grants.nih.gov/grants/policy/awardconditions.htm
for additional award applicability information.

 

In accordance with P.L. 110-161, compliance with
the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: 
http://publicaccess.nih.gov/.

 

This award represents the final year of the competitive
segment for this grant. Therefore, see the NIH Grants Policy Statement Section 8.6 Closeout for closeout requirements at: 
http://grants.nih.gov/grants/policy/#gps .

 

A final Federal Financial Report (FFR) (SF 425)
must be submitted through the eRA Commons (Commons) within 90 days of the expiration date; see the NIH Grants Policy Statement
Section 8.6.1 Financial Reports, http://grants.nih.gov/grants/policy/#gps, for additional information on this submission
requirement. The final FFR must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations.
There must be no discrepancies between the final FFR expenditure data and the Payment Management System’s (PMS) cash transaction
data.

 

A Final Invention Statement and Certification form
(HHS 568), (not applicable to training, construction, conference or cancer education grants) must be submitted through the eRA
Commons (Commons) within 90 days of the expiration date.

 

Furthermore, unless an application for competitive
renewal is submitted, a final progress report must also be submitted within 90 days of the expiration date. Institute/Centers may
accept the progress report contained in competitive renewal (type 2) in lieu of a separate final progress report. Contact the awarding
IC for IC-specific policy regarding acceptance of a progress report contained in a competitive renewal application in lieu of a
separate final progress report.

 

NIH strongly encourages electronic submission of
the final progress report and the final invention statement through the Closeout feature in the Commons. If the final progress
report and final invention statement are not submitted through the Commons, a copy can be emailed or sent to the contacts listed
below. Copies of the HHS 568 form may be downloaded at:  http://grants.nih.gov/grants/forms.htm.

 

Submissions of the final progress report and HHS
568 may be e-mailed as PDF attachments to the NIH Central Closeout Center at: DeasCentralized@od.nih.gov.

 

Paper submissions of the final progress report and
the HHS 568 may be faxed to the NIH Central Closeout Center at 301-480-2304 or mailed to the NIH Central Closeout Center at the
following address:

 

NIH/OD/OER/DEAS

Central Closeout Center

6705 Rockledge Drive, Room 2207

Bethesda, MD 20892-7987 (for regular or U.S. Postal
Service Express mail)

Bethesda, MD 20817 (for other courier/express mail
delivery only)

 

The final progress report should include, at a minimum,
a summary of progress toward the achievement of the originally stated aims, a list of significant results (positive and/or negative),
a list of publications and the grant number. If human subjects were included in the research, the final progress report should
also address the following:

 

Report on the inclusion of gender and minority study
subjects (using the gender and minority

 

	 	4	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

 

    	 

    	 

    

 

Inclusion Enrollment Form as provided in the PHS
2590 and available at  http://grants.nih.gov/grants/forms.htm).

 

Where appropriate, indicate whether children were
involved in the study or how the study was relevant for conditions affecting children (see NIH Grants Policy Statement Section
4.1.15.7 Inclusion of Children as Subjects in Clinical Research at URL  http://grants.nih.gov/grants/policy/#gps).

 

Describe any data, research materials (such as cell
lines, DNA probes, animal models), protocols, software, or other information resulting from the research that is available to be
shared with other investigators and how it may be accessed.

 

Any other specific requirements set forth in the
terms and conditions of the award must also be addressed in the final progress report.

 

Note, if this is the final year of a competitive
segment due to the transfer of the grant to another institution, then not all the requirements stated above are applicable. Specifically
a Final Progress Report is not required. However, a final FFR is required and should be submitted electronically as noted above.
In addition, if not already submitted, the Final Invention Statement is required and should be sent directly the assigned Grants
Management Specialist.

 

Treatment of Program Income:

Additional Costs

 

	 	SECTION IV – HL Special Terms and Conditions – 1R43HL114298-01

 

FIXED FEE

The fixed fee provided as part of this grant award
is in addition to allowable direct and facilities and administrative costs. An equitable adjustment of the fee will be made in
the event the grant is terminated. The fee should be drawn down from the DHHS Payment Management System, phone number 301-443-1660
in increments based upon the percentage of completion of the project.

 

BUDGET PERIOD

This award is issued for less than a 12-month budget
period in order to distribute future noncompeting awards more evenly throughout the fiscal year. The project period end date has
been adjusted accordingly.

 

KEY PERSONNEL

In addition to the PI, any absence, replacement,
or substantial reduction in effort of the following individual(s) below, requires written prior approval of the National Institutes
of Health awarding component.

 

Dr. Itzhak Goldberg

 

INTELLECTUAL PROPERTY RIGHTS

Normally, the grantee organization retains the principal
worldwide patent rights to any invention developed with United States government support. Under Title 37 Code of Federal Regulations
Part 401, the Government receives a royalty-free license for its use, reserves the right to require the patent holder to license
others in certain circumstances, and requires that anyone exclusively licensed to sell the invention in the United States must
normally manufacture it substantially in the United States. To the extent authorized by Title 35 United States Code Section 205,
the Government will not make public any information disclosing a Government-supported invention for a 4-year period to allow the
grantee organization a reasonable time to file a patent application, nor will the Government release any information that is part
of that application.

 

COST PRINCIPLES

Allowable costs of activities conducted by for-profit
organizations will be determined by applying the contract cost principles and procedures set forth in part 31 of the Federal Acquisition
Regulations (FAR). However, independent research and development costs (including the facilities and administrative costs allocable
to them) are unallowable.

 

AUDIT REQUIREMENTS

The Code of Federal Regulations (Title 45 Part
74.26) stipulates that commercial (for-profit) organizations are subject to the audit when its cumulative Federal awards
exceed $500,000 (as either a direct grantee and/or consortium participant) the Grantee may choose to follow the OMB A-133
Audit procedures or perform a GAAP/GAAS (Yellow Book) audit. Please refer to the Division of Financial Advisory Services website at
http://oamp.od.nih.gov/dfas/faqforprofitaudits.asp for additional information.

 

	 	5	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

 

 

PRIOR APPROVAL

Prior approval from the awarding office is required
for the following actions:

 

1.  Change in scope or objectives of the
grant-supported activities.The following actions are likely to be considered a change in scope:

a.  Change in the
specific aims approved at the time of award.

b.  Substitution
of one animal model for another.

c.  Any change from
the approved use of animals or human subjects

d.  Shifting the
emphasis of the research from one disease area to another.

e.  Applying a new
technology, i.e., changing assays from those approved to use of a different type of assay.

g.  Change in key
personnel whose expertise is critical to the approved project.

h.  Significant rebudgeting
whether or not it requires approval under rules governing budget changes. Significant rebudgeting occurs when the cumulative
amount of transfers among direct cost categories for the current budget period exceeds 25 percent of the total amount awarded, or $250,000,
whichever is less.

i.  Incurrence of
patient care costs not previously approved by NIH and/or when a grantee desires to rebudget funds out of the patient care category

 

2.  Change in Principal
Investigator or other key personnel identified on the Notice of Grant Award.

 

3.  Change of grantee
organization, successor in interest, or recipient institution name change.

 

4.  Deviations from special terms or conditions
stated on the Notice of Grant Award require prior approval from the NIH awarding office.

 

5.  Transferring
substantive programmatic work to a third party.

 

6.  Extensions
of the Budget/Project Period with or without additional funds.

 

7.  Patient care costs not previously approved
by NIH and/or when a grantee desires to rebudget funds out of the patient care category.

 

8.  Preaward costs incurred more than 90
days prior to the effective date of any new or competing continuation award.

 

9.  Actions requiring
additional federal funds.

 

Such prior approval should be requested in a letter
signed by the Principal Investigator and a Business Official of the grantee organization, should be addressed to the Grants Management
Specialist identified on the Notice of Grant Award, and should include an explanation and justification for the action(s). The
above is an abbreviated list and does not include all actions which require prior approval. If there are any questions as to whether
an action requires prior approval, contact the Grants Management Specialist listed below.

 

INFORMATION FOR GRANTEES

This term provides the URL for the NIH Welcome Wagon
letter. The intent of this memorandum is to highlight key requirements, provide referrals to important sources of information available
from the NIH, and identify NIH and Department of Health and Human Services (HHS) offices having responsibility for certain administrative
functions. http://grants.nih.gov/grants/funding/welcomewagon.htm

 

STAFF CONTACTS

 

The Grants Management Specialist is responsible for
the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions.
The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work
together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should
be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

 

	 	6	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

 

    	 

    	 

    

 

Grants Management Specialist: Mary S Baylor

Email: baylorm@nhlbi.nih.gov Phone:
301-435-0480 Fax: (301) 451-5462

 

Program Official: Lisa Schwartz

Email: schwartzlongal@mail.nih.gov Phone:
301-402-4826 Fax: 301-480-0560

 

SPREADSHEET SUMMARY

GRANT NUMBER: 1R43HL114298-01

 

INSTITUTION: ANGION BIOMEDICA CORPORATION

 

	Budget	 	 	Year
                                         1	 
	Salaries and Wages	 	$	[***]	 
	Fringe Benefits	 	$	[***]	 
	Supplies	 	$	[***]	 
	Travel Costs	 	$	[***]	 
	FEE	 	$	[***]	 
	TOTAL FEDERAL DC	 	$	[***]	 
	TOTAL FEDERAL F&A	 	$	[***]	 
	TOTAL COST	 	$	[***]	 

 

	Facilities
    and Administrative Costs	 	Year
    1	 
	F&A Cost Rate 1	 	 	90	%
	F&A Cost Base 1	 	$	[***]	 
	F&A Costs 1	 	$	[***]	 

 

	 	7	Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]